British Patient Capital has invested in Epsilogen, a London-based developer of novel therapeutic antibodies to treat cancer, as part of a GBP30.75m Series B funding round.
The investment has been made via Future Fund: Breakthrough, a GBP375 million programme where BPC co-invests with private sector investors in innovative, R&D-intensive UK companies.
Based at the London BioScience Innovation Centre, Epsilogen is working with immunoglobulin E (IgE) antibodies to develop new therapeutic treatments for solid tumours.
